Benjamin Oakes, Scribe Therapeutics CEO

Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

Scribe Ther­a­peu­tics found an­oth­er part­ner, this time with Pre­vail Ther­a­peu­tics, a sub­sidiary of Eli Lil­ly, in a $75 mil­lion up­front deal for neu­ro­mus­cu­lar and neu­ro­log­i­cal dis­eases.

Un­like Scribe’s ex vi­vo NK cell ther­a­py part­ner­ship with Sanofi that was an­nounced last fall, the Pre­vail pact is on ex­clu­sive terms for Scribe’s in vi­vo “CRISPR by De­sign” tech­nol­o­gy. Scribe al­so has a col­lab­o­ra­tion with Bio­gen on gene ther­a­py for ALS.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters